AQST — Aquestive Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1398733 ·
Last close
$3.70
Market Cap
$465.04M
52W High
$6.74
52W Low
$2.93
ADV30
2,489,512
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 7,557,000 | 3,951,000 | -14,469,000 | -16,496,000 | 119,327,000 | 90,349,000 | 190,151,000 |
| Jun 2026 | 13,819,000 | 9,802,000 | -8,223,000 | -22,864,000 | 132,104,000 | 98,490,000 | 188,690,000 |
| Mar 2026 | 14,446,000 | 10,977,000 | -4,204,000 | -8,057,000 | 141,125,000 | 110,734,000 | 175,179,000 |
| Dec 2025 | 13,015,000 | 7,179,000 | -28,839,000 | -31,860,000 | 160,425,000 | 121,169,000 | 194,087,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-39,762,000
Investing CF
$-933,000
Financing CF
$1,981,000
CapEx
$-933,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.64
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-494,415,000
Inventory
$7,309,000
Receivables
$5,254,000
ST Investments
—
EBIT TTM
$-64,348,000
Pretax Income TTM
$-79,277,000
Interest Exp TTM
$14,929,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$48,837,000
EBITDA
$-55,174,000
Free Cash Flow
$-22,574,000
Enterprise Value
$422,155,616
Total Cash
$90,349,000
Total Debt
$58,772,000
Shares Out
125,687,705
Trailing EPS
$-0.65
Book Value
$-0.56
ROE
—
ROA
-24.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 44,545,000 | -71,051,000 | -83,784,000 | 160,425,000 | 194,087,000 | -33,662,000 | -52,432,000 |
| Dec 2024 | 57,561,000 | -30,771,000 | -44,137,000 | 101,424,000 | 161,580,000 | -60,156,000 | -35,759,000 |
| Dec 2023 | 50,583,000 | -15,102,000 | -7,870,000 | 57,418,000 | 163,905,000 | -106,487,000 | -6,380,000 |
| Dec 2022 | 47,680,000 | -42,066,000 | -54,410,000 | 57,070,000 | 175,624,000 | -118,554,000 | -9,819,000 |
TTM Snapshot
Revenues TTM
$54,087,000
NetIncome TTM
$-78,227,000
OpCashFlow TTM
—
Assets (Latest)
$132,104,000
Forward EPS
$-0.50
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $3.00 · spot: $3.78 · call volume: 60 · put volume: 6,278
Expected Move to 2026-12-18:
±$0.60
(15.87%) —
implied range
$3.18 –
$4.38
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| STTK | Shattuck Labs, Inc. | $467.46M | $4.59 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $460.74M | $22.50 | — |
| KMDA | KAMADA LTD | $470.92M | $8.16 | — |
| AMRN | AMARIN CORP PLC\UK | $473.82M | $11.27 | — |
| NGNE | Neurogene Inc. | $478.19M | $23.10 | — |
News headlines (Yahoo Finance, 1h cache)
Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference
2026-11-18 12:00 · Yahoo
Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
2026-11-09 12:00 · Yahoo
Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks Anifilm ...
2026-11-06 19:05 · Yahoo
Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
2026-11-05 12:00 · Yahoo
Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-04 17:57 · Yahoo
Aquestive (AQST) Q3 2026 Earnings Call Transcript
2026-11-04 17:05 · Yahoo
What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call
2026-11-04 16:14 · Yahoo
Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates
2026-11-03 21:15 · Yahoo
Aquestive Therapeutics: Q3 Earnings Snapshot
2026-11-03 21:14 · Yahoo
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-03 21:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.